JP2021513347A5 - - Google Patents
Info
- Publication number
- JP2021513347A5 JP2021513347A5 JP2020542884A JP2020542884A JP2021513347A5 JP 2021513347 A5 JP2021513347 A5 JP 2021513347A5 JP 2020542884 A JP2020542884 A JP 2020542884A JP 2020542884 A JP2020542884 A JP 2020542884A JP 2021513347 A5 JP2021513347 A5 JP 2021513347A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- immune
- cells
- item
- locus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023112162A JP2023118962A (ja) | 2018-02-11 | 2023-07-07 | 非ｈｌａ制限ｔ細胞受容体およびその使用 |
| JP2025145426A JP2025172139A (ja) | 2018-02-11 | 2025-09-02 | 非ｈｌａ制限ｔ細胞受容体およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862629072P | 2018-02-11 | 2018-02-11 | |
| US62/629,072 | 2018-02-11 | ||
| PCT/US2019/017525 WO2019157454A1 (en) | 2018-02-11 | 2019-02-11 | Non-hla restricted t cell receptors and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023112162A Division JP2023118962A (ja) | 2018-02-11 | 2023-07-07 | 非ｈｌａ制限ｔ細胞受容体およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021513347A JP2021513347A (ja) | 2021-05-27 |
| JP2021513347A5 true JP2021513347A5 (enExample) | 2022-02-21 |
Family
ID=67548607
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020542884A Pending JP2021513347A (ja) | 2018-02-11 | 2019-02-11 | 非ｈｌａ制限ｔ細胞受容体およびその使用 |
| JP2023112162A Pending JP2023118962A (ja) | 2018-02-11 | 2023-07-07 | 非ｈｌａ制限ｔ細胞受容体およびその使用 |
| JP2025145426A Pending JP2025172139A (ja) | 2018-02-11 | 2025-09-02 | 非ｈｌａ制限ｔ細胞受容体およびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023112162A Pending JP2023118962A (ja) | 2018-02-11 | 2023-07-07 | 非ｈｌａ制限ｔ細胞受容体およびその使用 |
| JP2025145426A Pending JP2025172139A (ja) | 2018-02-11 | 2025-09-02 | 非ｈｌａ制限ｔ細胞受容体およびその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20200368283A1 (enExample) |
| EP (1) | EP3749687A4 (enExample) |
| JP (3) | JP2021513347A (enExample) |
| KR (1) | KR102828999B1 (enExample) |
| CN (1) | CN111886243A (enExample) |
| AU (2) | AU2019216982B2 (enExample) |
| BR (1) | BR112020016138A2 (enExample) |
| CA (1) | CA3090791A1 (enExample) |
| IL (2) | IL314563A (enExample) |
| MX (1) | MX2020008390A (enExample) |
| SG (1) | SG11202007622SA (enExample) |
| WO (1) | WO2019157454A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019157454A1 (en) | 2018-02-11 | 2019-08-15 | Memorial Sloan-Kettering Cancer Center | Non-hla restricted t cell receptors and uses thereof |
| US20210207174A1 (en) * | 2018-05-25 | 2021-07-08 | The Regents Of The University Of California | Genetic engineering of endogenous proteins |
| EP4110356A4 (en) * | 2020-02-28 | 2024-03-27 | Wisconsin Alumni Research Foundation | NON-VIRAL GENERATION OF CHIMERIC ANTIGEN RECEPTOR T CELLS OBTAINED BY GENE EDITING |
| EP4188395A1 (en) | 2020-07-30 | 2023-06-07 | Institut Curie | Immune cells defective for socs1 |
| WO2022116877A1 (en) | 2020-12-02 | 2022-06-09 | Shanghai Henlius Biotech, Inc. | ANTI-GARP/TGFβ ANTIBODIES AND METHODS OF USE |
| KR20230118887A (ko) | 2020-12-03 | 2023-08-14 | 센츄리 쎄라퓨틱스 인코포레이티드 | 유전자 조작 세포 및 이의 용도 |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| AR124414A1 (es) | 2020-12-18 | 2023-03-22 | Century Therapeutics Inc | Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable |
| CN114957481A (zh) * | 2021-02-25 | 2022-08-30 | 华夏英泰（北京）生物技术有限公司 | 针对cd19和cd22的双靶点star |
| US20250352577A1 (en) | 2021-03-11 | 2025-11-20 | Mnemo Therapeutics | Tumor neoantigenic peptides and uses thereof |
| AU2022233019A1 (en) | 2021-03-11 | 2023-09-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Tumor neoantigenic peptides |
| KR20240006721A (ko) | 2021-03-11 | 2024-01-15 | 엥스띠뛰 퀴리 | 막 형질 전환 네오 안티젠 펩타이드 |
| CA3212596A1 (en) | 2021-04-26 | 2022-11-03 | Michel Sadelain | Chimeric receptors targeting adgre2 and/or clec12a and uses thereof |
| WO2022233956A1 (en) | 2021-05-05 | 2022-11-10 | Immatics Biotechnologies Gmbh | Antigen binding proteins specifically binding prame |
| KR20240122784A (ko) | 2021-12-17 | 2024-08-13 | 상하이 헨리우스 바이오테크, 인크. | 항-ox40 항체 및 사용 방법 |
| KR20240116755A (ko) | 2021-12-17 | 2024-07-30 | 상하이 헨리우스 바이오테크, 인크. | 항-ox40 항체, 다중 특이적 항체 및 이의 사용 방법 |
| JP2025501272A (ja) | 2021-12-28 | 2025-01-17 | ムネモ・セラピューティクス | 不活性化されたｓｕｖ３９ｈ１及び改変ｔｃｒを有する免疫細胞 |
| WO2023139269A1 (en) | 2022-01-21 | 2023-07-27 | Mnemo Therapeutics | Modulation of suv39h1 expression by rnas |
| CA3245762A1 (en) | 2022-03-25 | 2023-09-28 | Shanghai Henlius Biologics Co., Ltd. | ANTI-MSLN ANTIBODIES AND METHODS OF USE |
| EP4279085A1 (en) | 2022-05-20 | 2023-11-22 | Mnemo Therapeutics | Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease |
| WO2023237541A1 (en) * | 2022-06-07 | 2023-12-14 | Gadeta B.V. | Delta t-cell or gamma t-cell receptor chains or parts thereof that mediate an anti-tumour or anti-infective response |
| WO2024062138A1 (en) | 2022-09-23 | 2024-03-28 | Mnemo Therapeutics | Immune cells comprising a modified suv39h1 gene |
| WO2025125363A1 (en) | 2023-12-11 | 2025-06-19 | Institut National de la Santé et de la Recherche Médicale | Host cells engineered to bypass the cd28 co-stimulation pathway and uses thereof for inducing durable immune responses under non-inflammatory conditions |
| WO2025163107A1 (en) | 2024-02-01 | 2025-08-07 | Institut Gustave Roussy | Immune cells defective for znf217 and uses thereof |
| WO2025252855A1 (en) | 2024-06-05 | 2025-12-11 | Institut National de la Santé et de la Recherche Médicale | IL-15 MUTEINS WITH PH-DEPENDENT BINDING FOR IL-15Rbeta |
| WO2025252857A1 (en) | 2024-06-05 | 2025-12-11 | Institut National de la Santé et de la Recherche Médicale | Il-15 muteins with ph-dependent binding for il-15ralpha |
| WO2026002973A1 (en) | 2024-06-25 | 2026-01-02 | Institut National de la Santé et de la Recherche Médicale | Host immune cells engineered to overexpress a foxk1 polypeptide |
| WO2026062222A1 (en) | 2024-09-20 | 2026-03-26 | Institut Curie | Novel protein isoforms and uses |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| JPS6412935A (en) | 1987-07-02 | 1989-01-17 | Mitsubishi Electric Corp | Constant-speed travel device for vehicle |
| IL86278A (en) * | 1988-05-04 | 2003-06-24 | Yeda Res & Dev | Endowing cells with antibody specificity using chimeric t cell receptor |
| US5906936A (en) * | 1988-05-04 | 1999-05-25 | Yeda Research And Development Co. Ltd. | Endowing lymphocytes with antibody specificity |
| US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
| US5843728A (en) * | 1991-03-07 | 1998-12-01 | The General Hospital Corporation | Redirection of cellular immunity by receptor chimeras |
| US20020018783A1 (en) | 1997-03-20 | 2002-02-14 | Michel Sadelain | Fusion proteins of a single chain antibody and cd28 and uses thereof |
| US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| US9273283B2 (en) * | 2009-10-29 | 2016-03-01 | The Trustees Of Dartmouth College | Method of producing T cell receptor-deficient T cells expressing a chimeric receptor |
| ES2654060T3 (es) | 2011-10-20 | 2018-02-12 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Receptores de antígenos quiméricos anti-CD22 |
| BR112014029417B1 (pt) * | 2012-05-25 | 2023-03-07 | Cellectis | Método ex vivo para a preparação de células t para imunoterapia |
| MX370148B (es) | 2012-10-02 | 2019-12-03 | Memorial Sloan Kettering Cancer Center | Composiciones y su uso para inmunoterapia. |
| TR201905447T4 (tr) * | 2012-12-14 | 2019-05-21 | Biontech Rna Pharmaceuticals Gmbh | Yeni mhc bağımsız tümörle ilişkili antijenler. |
| US9937207B2 (en) * | 2013-03-21 | 2018-04-10 | Sangamo Therapeutics, Inc. | Targeted disruption of T cell receptor genes using talens |
| AR099812A1 (es) * | 2014-03-21 | 2016-08-17 | Abbvie Inc | Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr |
| US20170335331A1 (en) * | 2014-10-31 | 2017-11-23 | The Trustees Of The University Of Pennsylvania | Altering Gene Expression in CART Cells and Uses Thereof |
| WO2016180468A1 (en) * | 2015-05-11 | 2016-11-17 | Biontech Cell & Gene Therapies Gmbh | Claudin-18.2-specific immunoreceptors and t cell epitopes |
| PL3298033T5 (pl) | 2015-05-18 | 2023-10-30 | TCR2 Therapeutics Inc. | Kompozycje i zastosowania medyczne do reprogramowania TCR z zastosowaniem białek fuzyjnych |
| US10752670B2 (en) * | 2015-05-20 | 2020-08-25 | Cellectis | Anti-GD3 specific chimeric antigen receptors for cancer immunotherapy |
| JP6816133B2 (ja) * | 2015-10-05 | 2021-01-20 | プレシジョン バイオサイエンシズ，インク． | 改変ヒトｔ細胞受容体アルファ定常領域遺伝子を含む遺伝子改変細胞 |
| MX2018004721A (es) * | 2015-10-23 | 2018-07-06 | Eureka Therapeutics Inc | Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas. |
| AU2016361451B2 (en) * | 2015-11-27 | 2024-01-25 | Cartherics Pty. Ltd. | Genetically modified cells and uses thereof |
| BR112018012235A2 (pt) * | 2015-12-18 | 2018-12-04 | Sangamo Therapeutics Inc | rompimento alvejado do receptor de células de mhc |
| GB201604494D0 (en) * | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Transfected T-Cells and T-Cell receptors for use in immunotherapy against cancers |
| EP4628587A3 (en) * | 2016-04-15 | 2026-02-25 | Memorial Sloan Kettering Cancer Center | Transgenic t cell and chimeric antigen receptor t cell compositions and related methods |
| WO2017192536A1 (en) | 2016-05-02 | 2017-11-09 | University Of Kansas | Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy |
| WO2018067993A1 (en) * | 2016-10-07 | 2018-04-12 | TCR2 Therapeutics Inc. | Compositions and methods for t-cell receptors reprogramming using fusion proteins |
| TWI785009B (zh) * | 2017-02-14 | 2022-12-01 | 美商凱特製藥公司 | Ｃｄ７０結合分子及使用彼之方法 |
| US11512287B2 (en) * | 2017-06-16 | 2022-11-29 | Sangamo Therapeutics, Inc. | Targeted disruption of T cell and/or HLA receptors |
| WO2019157454A1 (en) * | 2018-02-11 | 2019-08-15 | Memorial Sloan-Kettering Cancer Center | Non-hla restricted t cell receptors and uses thereof |
-
2019
- 2019-02-11 WO PCT/US2019/017525 patent/WO2019157454A1/en not_active Ceased
- 2019-02-11 EP EP19751805.3A patent/EP3749687A4/en active Pending
- 2019-02-11 CN CN201980019097.1A patent/CN111886243A/zh active Pending
- 2019-02-11 IL IL314563A patent/IL314563A/en unknown
- 2019-02-11 SG SG11202007622SA patent/SG11202007622SA/en unknown
- 2019-02-11 IL IL276554A patent/IL276554B2/en unknown
- 2019-02-11 KR KR1020207025816A patent/KR102828999B1/ko active Active
- 2019-02-11 CA CA3090791A patent/CA3090791A1/en active Pending
- 2019-02-11 BR BR112020016138-1A patent/BR112020016138A2/pt unknown
- 2019-02-11 MX MX2020008390A patent/MX2020008390A/es unknown
- 2019-02-11 JP JP2020542884A patent/JP2021513347A/ja active Pending
- 2019-02-11 AU AU2019216982A patent/AU2019216982B2/en active Active
-
2020
- 2020-08-11 US US16/990,185 patent/US20200368283A1/en active Pending
- 2020-10-20 US US17/075,142 patent/US11229669B2/en active Active
-
2021
- 2021-10-19 US US17/505,515 patent/US12036244B2/en active Active
-
2023
- 2023-07-07 JP JP2023112162A patent/JP2023118962A/ja active Pending
-
2024
- 2024-09-26 AU AU2024220100A patent/AU2024220100A1/en active Pending
-
2025
- 2025-09-02 JP JP2025145426A patent/JP2025172139A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021513347A5 (enExample) | ||
| IL276554B1 (en) | Non-hla restricted t cell receptors and uses thereof | |
| Bollino et al. | Chimeric antigen receptor–engineered natural killer and natural killer T cells for cancer immunotherapy | |
| Yousefi et al. | Immunotherapy of cancers comes of age | |
| Lipowska-Bhalla et al. | Targeted immunotherapy of cancer with CAR T cells: achievements and challenges | |
| Zhang et al. | Engineering car-t cells | |
| Li et al. | Increasing the safety and efficacy of chimeric antigen receptor T cell therapy | |
| Dai et al. | Chimeric antigen receptors modified T-cells for cancer therapy | |
| Mackall et al. | Immune-based therapies for childhood cancer | |
| Zhao et al. | A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity | |
| Helmy et al. | Cancer immunotherapy: accomplishments to date and future promise | |
| Shi et al. | Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects | |
| JP2022550899A5 (enExample) | ||
| JP2022531222A5 (enExample) | ||
| Park et al. | Adoptive immunotherapy for B-cell malignancies with autologous chimeric antigen receptor modified tumor targeted T cells | |
| Essand et al. | Genetically engineered T cells for the treatment of cancer | |
| JP2017503472A5 (enExample) | ||
| JP2020517259A5 (enExample) | ||
| JP7851337B2 (ja) | キメラ抗原受容体を発現する粘膜関連インバリアントｔ（ｍａｉｔ）細胞 | |
| JP2022543742A5 (enExample) | ||
| RU2017114174A (ru) | Композиции и способы для бустинга эффективности адоптивной клеточной иммунотерапии | |
| JP2017531687A5 (enExample) | ||
| Turtle | Chimeric antigen receptor modified T cell therapy for B cell malignancies | |
| Junghans | The challenges of solid tumor for designer CAR-T therapies: a 25-year perspective | |
| JP2023549098A5 (enExample) |